Consensus Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
4 ^USD	+6.38%		+3.63%	-53.33%

05-10	Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	MT
05-10	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	CI

Evolution of the average Target Price on Intensity Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b5083b8a07d7ee4a51f24.FLAZjjfdcvLFULyVyn7B-V-0GChYxMTmegOF1UUDKXQ.RtEh3l-FFaOJN_rj_CqVjW77QEYfpfCOAEjapSdweyZA22O6eZcXkaYE5Q~f23f08996ce8c861e644f2e990536b28